AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30358715
Drug: 1.25‐mg conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25‐mg conjugated equine estrogen vaginal cream (Premarin Vaginal Cream)
Trial: 22409735
Drug: Four weekly
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weekly multiprofessional senior group meetings with one follow-up home visit
Trial: 18602429
Drug: High LC
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High LC n-3 FA (>1300 mg/day)
Trial: 18602429
Drug: Low LC
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low LC n-3 FA (<260 mg/day)
Trial: 10520385
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with morphine intravenously by a PCA Plus Micro Delivery Device for at least 48 hours
Trial: 10520385
Drug: Nurse-administered intravenous
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered intravenous morphine followed by oral acetaminophen with or without codeine in 24 to 36 hours
Trial: 1935862
Drug: Sandocal containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandocal containing 1 g of effervescent calcium
Trial: 1935862
Drug: Calsup containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calsup containing 1 g of calcium as the carbonate
Trial: 1935862
Drug: Caltrate containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caltrate containing 1.2 g of calcium as the carbonate
Trial: 7042111
Drug: Acebutolol 200
RxNorm normalized name: acebutolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 200 mg thrice daily
Trial: 7042111
Drug: Acebutolol 400
RxNorm normalized name: acebutolol 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 400 mg thrice daily
Trial: 30053956
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (FF/VI; 100/25 or 200/25 μg)
Trial: 30053956
Drug: Twice-daily inhaled
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA)
Trial: 25274615
Drug: Bevacizumab 5
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5 mg/kg with WBRT (30 Gy/15 fractions/3 weeks)
Trial: 25274615
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg with WBRT (30 Gy/15 fractions/3 weeks)
Trial: 25274615
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg with WBRT (30 Gy/10 fractions/2 weeks)
Trial: 25274615
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (Bevacizumab combined with WBRT)
Trial: 19647405
Drug: Noninvasive coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive coronary flow reserve (CFR) assessment using intravenous adenosine infusion
Trial: 17284138
Drug: Intramuscular aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular aripiprazole 5.25 mg
Trial: 17284138
Drug: Intramuscular aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular aripiprazole 15 mg
Trial: 17284138
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol 7.5 mg
Trial: 12571942
Drug: New fumanling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New fumanling cream
Trial: 3065158
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) (n = 48)
Trial: 3065158
Drug: Intensified conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified conventional treatment (ICT) (n = 41)
Trial: 3065158
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (CT) (n = 28)
Trial: 23663752
Drug: All apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All apremilast doses
Trial: 19192663
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus CIK cell transfusion
Trial: 12958052
Drug: Physostigmine (PHYS)
DrugBank: Physostigmine (DB00981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (PHYS) 0.12 microg/minute/kg, 7-hour infusion
Trial: 9417492
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no selenium treatment)
Trial: 30219886
Drug: 1-year trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1-year trastuzumab plus chemotherapy (arm A, long)
Trial: 30219886
Drug: 9 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 weeks trastuzumab plus chemotherapy (arm B, short)
Trial: 26369284
Drug: Rapid advancement
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid advancement (36 ml/kg/day)
Trial: 26369284
Drug: High initiation
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High initiation (24 ml/kg/day)
Trial: 26369284
Drug: Low initiation
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low initiation (4 ml/kg/day)
Trial: 26369284
Drug: Low advancement
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low advancement (24 ml/kg/day)
Trial: 26369284
Drug: High advancement
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High advancement (36 ml/kg/day)
Trial: 24585432
Drug: YSP Amoxicillin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YSP Amoxicillin® capsule
Trial: 22909146
Drug: Oxybutynin chloride
RxNorm normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin chloride topical gel (OTG) 10% applied once daily (1g, 100mg oxybutynin)
Trial: 22909146
Drug: Immediate-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release oxybutynin (OXB-IR) 5mg capsule three times/day
Trial: 20575621
Drug: Diclofenac epolamine
RxNorm normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac epolamine 1.3% topical patch (DETP) applied once daily for 7 days
Trial: 15138297
Drug: FTY720 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 1 mg alone
Trial: 15138297
Drug: Cyclosporine 200
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 200 mg twice daily
Trial: 15138297
Drug: FTY720 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 1 mg with cyclosporine
Trial: 11585480
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration of antenatal corticosteroids (betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses every week until 34 weeks' gestation or delivery)
Trial: 11585480
Drug: Single course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single course of antenatal corticosteroids (either betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses, or dexamethasone, 6 mg intramuscularly repeated every 12 hours for 4 doses)
Trial: 855849
Drug: Fat excretion
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat excretion
Trial: 30707361
Drug: Repeat Botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat Botulinum toxin 100 U injections
Trial: 24226381
Drug: Tropisetron as
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron as a single medication (Group IV)
Trial: 17275889
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin and pelvic radiation (GOG 120)
Trial: 17275889
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin and pelvic radiation (GOG 165)
Trial: 11831543
Drug: lovastatin immediate-release
RxNorm normalized name: lovastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin immediate-release (IR) 40 mg tablets following a standard breakfast
Trial: 11831543
Drug: lovastatin extended-release
RxNorm normalized name: Lovastatin Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin extended-release (ER) 40 mg tablets following a standard breakfast
Trial: 11831543
Drug: lovastatin extended-release
RxNorm normalized name: Lovastatin Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin extended-release (ER) 40 mg tablets under fasting conditions
Trial: 11831543
Drug: lovastatin extended-release
RxNorm normalized name: Lovastatin Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin extended-release (ER) tablets with breakfast
Trial: 7728285
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (1 g/d)
Trial: 2140332
Drug: Topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracycline applied twice daily for 16 weeks
Trial: 2140332
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied twice daily for 16 weeks
Trial: 6101956
Drug: Clorazepate dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate dipotassium 5 mg
Trial: 6101956
Drug: Clorazepate dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate dipotassium 7.5 mg
Trial: 6101956
Drug: Clorazepate dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate dipotassium 15 mg
Trial: 6101956
Drug: Clorazepate dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate dipotassium 7.5 mg/day for 14 days
Trial: 6101956
Drug: Clorazepate dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate dipotassium 15 mg/day for 14 days
Trial: 28100321
Drug: Esmolol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol treatment
Trial: 21331628
Drug: Functional beverage
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional beverage rich in vitamins C and E plus Lippia citriodora extract (PLX) containing 20 mg/100 ml verbascoside
Trial: 19726396
Drug: Anthracycline-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-based chemotherapy regimens (dose‐dense taxane, dose‐standard taxane, or dose‐standard without taxane)
Trial: 17056201
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg by mouth twice per day for 2 weeks before and during CRT
Trial: 17056201
Drug: Celecoxib administration
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib administration before CRT
Trial: 15163253
Drug: Beaded extended-release
RxNorm normalized name: minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beaded extended-release carbamazepine capsules (ERC-CBZ; SPD417) 200-1600 mg/day, mean dose 938 mg/day
Trial: 25411413
Drug: Combined dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combined dabrafenib and trametinib therapy (CombiDT) at standard dose (150/2)
Trial: 21698100
Drug: Acetaminophen (10-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (10-15 mg per kg)
Trial: 19490462
Drug: ketamine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 0.15 mg/kg i.v.
Trial: 19490462
Drug: ketamine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 0.15 mg/kg + midazolam 0.01 mg/kg i.v.
Trial: 11392343
Drug: Amantadine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (2.5 mg/kg per day for 1 week, then 5.0 mg/kg per day for 3 weeks)
Trial: 9251847
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms vaccine
Trial: 2422927
Drug: Somatostatin intravenous
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin intravenous drip (250 micrograms/h) for 4 hours, started at the beginning of operation
Trial: 27444119
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and drug treatment
Trial: 20542419
Drug: 10% benzocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% benzocaine gel (B10)
Trial: 12569689
Drug: rhEGF ointments
RxNorm normalized name: Hu-rhEGF-rP64k/Mont
DrugBank: Hu-rhEGF-rP64k/Mont (DB15781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEGF ointments of 10 micrograms/g
Trial: 3348613
Drug: Intravenous cefoperazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefoperazone (2 g) and sulbactam (1 g)
Trial: 3348613
Drug: Intraperitoneal cefoperazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cefoperazone (2 g) and sulbactam (1 g)
Trial: 31484660
Drug: DFMO (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO (500 mg orally) plus aspirin (325 mg)
Trial: 16458629
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (conjugated estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg)
Trial: 9256142
Drug: 0.075% capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075% capsaicin cream applied to the painful site four times daily for 8 weeks
Trial: 9256142
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied to the painful site four times daily for 8 weeks
Trial: 8509640
Drug: Recombinant IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant IFN alpha‐2b alone (5 MU s.c. thrice weekly for 5 months)
Trial: 8509640
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IFN alpha‐2b and recombinant IL‐2 (3 MU IFN alpha‐2b s.c. thrice weekly for 5 months, with IL-2 added starting at month 2)
Trial: 26790205
Drug: Shallow-layer embedding
RxNorm normalized name: Bayer Aspirin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shallow-layer embedding group (subcutaneous layer)
Trial: 23636088
Drug: Ultrasound-guided intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided intra-articular injection through midmedial portal
Trial: 23636088
Drug: Ultrasound-guided intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided intra-articular injection through midlateral portal
Trial: 23636088
Drug: Ultrasound-guided intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided intra-articular injection through superolateral portal
Trial: 16855169
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg, twice/weekly) and Infliximab (3 mg/kg on 0, 2, 6, and every 8 weeks thereafter)
Trial: 16855169
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (stable therapy with prednisone and MTX without anti-TNF-alpha therapy)
Trial: 12623939
Drug: Co‐amilozide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co‐amilozide (25 mg hydrochlorothiazide and 2.5 mg amiloride) daily
Trial: 11180916
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (menatetrenone, 45 mg/day)
Trial: 11180916
Drug: Calcium (calcium
RxNorm normalized name: Slow-Mag with Calcium (calcium carbonate 298 MG (calcium 119 MG) / magnesium chloride 596 MG (magnesium 71.5 MG)) Delayed Release Oral Tablet, Reformulated Feb 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (calcium lactate, 2 g/day)
Trial: 29863955
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus bevacizumab plus chemotherapy (ABCP)
Trial: 17437819
Drug: Adjuvant weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant weekly docetaxel (35 mg/m² weekly for 6 cycles, starting 4 to 12 weeks post-surgery)
Trial: 17437819
Drug: Adjuvant weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant weekly docetaxel
Trial: 27610820
Drug: Reduced-iodine-dose dual-energy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-iodine-dose dual-energy CTA (21-27 g I)
Trial: 27610820
Drug: Standard-iodine-dose single-energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-iodine-dose single-energy CTA (30-37 g I)
Trial: 24467257
Drug: Tobacco treatment
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco treatment intervention
Trial: 22088576
Drug: Gentamicin 320
RxNorm normalized name: sodium citrate 4% Gentamicin 320mcg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 320 μg/mL in 4% sodium citrate
Trial: 22088576
Drug: Heparin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 1,000 U/mL
Trial: 22276283
Drug: Buprenorphine (BUP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (BUP; 2 mg)
Trial: 22276283
Drug: Buprenorphine (BUP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (BUP; 8 mg)
Trial: 22276283
Drug: Buprenorphine/Naloxone (BUP/NX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/Naloxone (BUP/NX; 2 mg buprenorphine + 0.5 mg naloxone)
Trial: 22276283
Drug: Buprenorphine/Naloxone (BUP/NX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/Naloxone (BUP/NX; 8 mg buprenorphine + 2 mg naloxone)
Trial: 10609378
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (anticoagulants)
Trial: 1789091
Drug: Soft hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft hydrogel (IO-gel) lens
Trial: 23344273
Drug: Immediate oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate oxytocin infusion
Trial: 23344273
Drug: Delayed oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed oxytocin infusion (4 hours)
Trial: 21214631
Drug: Adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (80 mg at week 0; 40 mg every other week from weeks 1-15) with topical vehicle
Trial: 21214631
Drug: Adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (80 mg at week 0; 40 mg every other week from weeks 1-15) with topical calcipotriol/betamethasone dipropionate (C/B)
Trial: 21214631
Drug: Adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (80 mg at week 0; 40 mg every other week from weeks 1-15)
Trial: 18260869
Drug: Atorvastatin (10.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10.8 +/- 0.1 mg/day)
Trial: 11380321
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (metronidazole, amoxicillin, bismuth subsalicylate for 2 weeks, followed by bismuth alone for 14 weeks)
Trial: 11380321
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy and calcium carbonate
Trial: 9661650
Drug: Leucine 54
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine 54 (L) polymorphism
Trial: 9661650
Drug: Genotype L/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype L/L